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INTRODUCTION
The tissue microarray (TMA) technique has been in use for 15 
years. The technology was first described in 1987, but its use 
took off 11 years later, when Kononen and colleagues devel-
oped a device that could rapidly and reproducibly produce 
TMAs (Kononen et al., 1998). This powerful, high-throughput 
technique can be used to assay hundreds of patient tissues 
arrayed on a single microscope slide.
THE TECHNIQUE
Following fixation, biopsies and excised tissue samples are usu-
ally embedded in paraffin blocks to facilitate their cutting on a 
microtome; this results in 5-µm tissue slides that can be stained 
with hematoxylin and eosin (H&E) and viewed under a micro-
scope. The paraffin blocks can also be used as source of material 
from which to construct a TMA. In this procedure, areas of inter-
est are marked on the H&E slides by a pathologist. Then, cylin-
drical tissue core biopsy specimens (Figure 1a) from the original 
formalin-fixed paraffin-embedded (FFPE) tissue donor blocks are 
punched out of the paraffin block using specialized TMA equip-
ment and placed in a predrilled hole in a (new) recipient paraf-
fin block at defined array coordinates (Jawhar, 2009; Camp et 
al., 2008). Sectioning of this recipient paraffin block will reveal 
a slide with numerous small, round tissue sections through the 
cores punched out of the original blocks; hence, each original 
tissue sample is represented by one or more small “histospots” 
with a preset fixed diameter ranging from 0.6 to 2 mm (Figure 
1b). The number of spots on a single slide depends on the core 
size, ranging from 40 to 800 spots (Camp et al., 2008). Cores 
are placed at specifically assigned coordinates, which typically 
are recorded in a spreadsheet. To facilitate “reading” of the TMA 
slide, different known tissue cores (e.g., liver, thyroid) are placed 
at the outer margins and empty holes are left at predefined plac-
es. After the TMA has been constructed, the recipient block is 
heated to 37 °C to fix the cores; then, using a microtome, sec-
tions are cut from the TMA blocks to generate TMA slides for 
analysis (Jawhar, 2009).
There are variations on the “normal” TMA procedure. The 
cutting-edge matrix assembly array is produced by cutting and 
stacking sections in a serial manner to produce arrays that rep-
resent hundreds of specimens. Some researchers have made a 
TMA using frozen tissue; others have used cell lines and needle 
biopsies (Camp et al., 2008).
APPLICATIONS
The increased use of new molecular biology techniques has 
revolutionized investigation of the pathogenesis and progres-
sion of diseases such as cancer. New markers, identified via 
molecular research in cellular and animal models, require 
clinical validation on histopathological human specimens. 
This translation from basic to clinical research is facilitated 
by the TMA technology, which enables investigators to screen 
for the expression of a specific protein on tissue samples from 
a large cohort of patients by immunohistochemistry or the 
presence of nucleotide sequences by in situ hybridization.
All applications currently performed on standard histo-
logical sections from FFPE tissue are possible using TMA. 
In contrast to a series of whole FFPE-tissue sections, stained 
separately via immunohistochemistry, the use of TMA slides 
allows semiquantitative scoring of the intensity of staining 
because all tissue samples on a TMA slide, including the con-
trols, have been exposed to the same amount of primary and 
secondary antibody and chromogen. For example, Zhou et 
al. (2013) stained a TMA composed of melanoma samples 
from 169 patients to evaluate expression of fibroblast growth 
factor–inducible protein 14 (Fn14) and applied semiquantita-
tive scoring (Figure 2) that enabled them to identify Fn14 as 
prognostic marker and therapeutic target in melanoma.
ADVANTAGES 
•  Allows high-throughput analysis of multiple 
specimens at the same time.
•  Allows semiquantitative scoring of 
immunohistochemical or hybridization signals.
•  Allows use of minimal quantities of tissue.
LIMITATIONS 
•  Cores may not be representative of the whole tumor 
owing to tumor heterogeneity; in a heterogeneous 
tumor, multiple cores must be taken.
•  Requires experienced personnel and expensive 
equipment.
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and same reagent concentration); therefore, samples can be 
compared and the immunohistochemical results can be read 
out in a semiquantitative way. The alternative of assessing the 
level of staining in separate histological whole sections is diffi-
cult because of subtle differences in intensity. When the cores 
are taken from pathologist-identified regions of interest, immu-
nohistochemical staining can often be scored reliably by indi-
viduals with only rudimentary training or the scoring can be 
done by an automated reader (Camp et al., 2008).
Decreased assay volume, time, and cost: only a small 
amount of each reagent is needed to assay all cores at the same 
time, compared with separately assaying standard histologic 
whole sections from each donor.
DISADVANTAGES
Tissue heterogeneity: one of the most common criticisms of TMA 
is that the small cores may not be representative of the entire 
tumor, owing to tumor heterogeneity. This heterogeneity differs 
from cancer to cancer; for example, it has been estimated at 71% 
for SCC compared with 50% for breast cancer (Li et al., 2010). 
The problem of tumor heterogeneity and consequent false-pos-
itive or false-negative results in the TMA slide can be overcome 
by including enough tissue cores per sample. Ideally, this number 
should be based on careful consideration before constructing the 
TMA, but in practice cores should be taken from all histologically 
divergent areas in the original sample, as divergent histology may 
result in divergent phenotype or genotype. In a previous study we 
took three or four cores from each vertical-growth-phase mela-
noma and obtained good concordance between immunohisto-
chemical and reverse transcriptase–PCR data (Winnepenninckx 
et al., 2006). Moreover, Jensen et al. (2011) obtained up to 96% 
agreement between TMA and whole-slide immunohistochemical 
data. Finally, the statistical power of analysis of hundreds of cases 
will largely eliminate the effect of variability of a single data point.
Detection of specific gene sequences using fluorescence 
in situ hybridization (FISH) of biopsy specimens from a large 
patient cohort (Chen and Chen, 2013) is another application 
of TMA. FISH can be used to detect the presence or absence 
of specific gene sequences as well as their location; this tech-
nique has been found useful in the differential diagnosis of 
ambiguous melanocytic lesions (Chen and Chen, 2013).
ADVANTAGES
Simultaneous analysis of a large number of specimens: TMA 
provides high-throughput data acquisition. For example, if 100 
consecutive sections from a TMA block containing 200 cores 
are used, 20,000 data points are obtained. In addition, the 
original blocks from which the cores were taken are conserved; 
a similar approach using the original block would require an 
enormous amount of labor and time—and, more importantly, 
consume the original paraffin block.
Construction of ex vivo tumor progression model: studying 
morphological and molecular changes through the stages of 
tumor progression is easily performed by constructing a TMA 
because it is possible to include different tumor progression 
stages. Figure 1a represents a TMA of squamous cell carcino-
ma (SCC) progression for which cores were taken from normal 
skin, in situ SCC, and invasive SCC of the same patient.
Experimental uniformity: in a TMA, each tissue core is 
treated in an identical manner (same antigen retrieval, same 
temperature, same incubation time, same washing procedure, 
Figure 1. Construction of a TMA. (a) Example of marked areas of interest 
on a hematoxylin and eosin slide indicating sites at which to punch out 
samples of normal skin and in situ and invasive squamous cell carcinoma 
(SCC). (b) Process of constructing a TMA. The area of interest is marked on 
a hematoxylin and eosin slide. The TMA core is taken out of the original 
donor block and arrayed in a recipient block using a TMA needle. Multiple 
sections can be cut from the recipient block for morphological and 
molecular studies. TMA, tissue microarray.
Figure 2. Scoring of a TMA. Semiquantitative scoring of a TMA 
immunostained with an anti-Fn14 antibody containing melanoma tissue. 
Reprinted with permission from Zhou et al., 2013. TMA, tissue microarray.
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High cost: commercial TMA builder machines such as auto-
mated and semiautomatic tissue arrayers are expensive. A rela-
tively simple and inexpensive alternative is the use of lab-made 
recipient paraffin blocks and ordinary cannula-piercing nee-
dles, skin biopsy punches, and bone marrow biopsy needles 
(Choi et al., 2012). However this alternative is time-consuming, 
and for large sample investigations, automated or semiauto-
matic arrayers may ultimately be less expensive.
Variations in antigenicity: given TMA’s ability to array many 
samples and to perform retrospective studies, variations in the 
antigenicity of stored archival samples may create problems.
COMPARISON WITH DNA MICROARRAYS
Every cell in the body contains a complete set of identical 
DNA; however, as a result of genetic and epigenetic mecha-
nisms, only certain genes are active in a given cell, differenti-
ating that cell from others (Villasenor-Park and Ortega-Loayza, 
2013). The active genes are transcribed into messenger RNA 
(mRNA), which is subsequently translated into proteins. These 
proteins are responsible for the behavior and function of the 
cell (Villasenor-Park and Ortega-Loayza, 2013). In contrast 
to cDNA microarrays, which focus on gene expression at the 
mRNA level but do not yield information on the final steps of 
translation to a protein, TMAs can provide information on the 
expression level and activity of the final product, the protein.
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1.  In constructing a TMA, the starting material most 
often used is:
A. Frozen tissue.
B. Needle-biopsy specimens.
C. FFPE tissue.
D. A cell line.
2.  TMA is a powerful, high-throughput technique 
owing to its ability to assay hundreds of patient tis-
sues arrayed on a single microscope slide for:
A.  DNA crosslinking.
B.  mRNA expression.
C.  Invasion capacity of a single cell.
D. Protein expression.
3.  Which statement does not apply to TMA?
A.  More than 150 samples can be studied at the 
same time.
B.  Only a small amount of reagent is needed to 
stain the samples.
C.  TMA is an excellent tool for examining hetero-
geneous tissue.
D.  TMA allows semiquantitative analysis of immu-
nohistochemical signals.
4.  Which statement is false?
A. A TMA can be made of frozen tissue.
B.  Different tumor-progression stadia can be 
studied from the same patient.
C.  Once a core is punched out from the original 
paraffin block, you cannot use it again.
D.  The antigenicity of the different samples is 
always the same, even that of stored archival 
samples.
5.  Which of the following is not an advantage of TMA?
A. Experimental uniformity.
B.  Simultaneous analysis of a large number of 
specimens.
C.  Decreased assay volume, time, and cost as com-
pared with assaying whole sections.
D. Results can be obtained in less than one day.
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